A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment ...

GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited evidence and unknown long-term risks.

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

GLP-1 receptor agonists appear to be associated with an increased risk for osteoporosis and other orthopedic conditions.

From 2023, there was a decrease in use of metabolic and bariatric surgery, with stronger decline for sleeve gastrectomy.

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy ...

Twenty percent of potentially eligible youth are prescribed GLP-1 RAs, with the odds of prescription higher with increasing ...

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had ...

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...